8-K

 1
================================================================================
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C.20549
                                 --------------

                                    FORM 8-K

                                 CURRENT REPORT
                                 --------------



                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
                     --------------------------------------


         Date of Report (Date of earliest event reported): March 31, 2003


                             BIOSPHERE MEDICAL, INC.
         --------------------------------------------------------------
             (Exact name of registrant as specified in its Charter)



        Delaware                      0-23678                     04-3216867
 -------------------------          ------------              -----------------
(State or Other Jurisdiction        (Commission                 (IRS Employer
   of Incorporation)                File Number)             Identification No.)



               1050 Hingham St. Rockland, Massachusetts 02370
              ----------------------------------------------------
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (781) 681-7900



              ----------------------------------------------------
          (Former Name or Former Address if Changed Since Last Report)

================================================================================


 2

ITEM 5. OTHER EVENTS

     On March 31, 2003, BioSphere Medical, Inc. issued a press release (which is
     attached hereto as Exhibit 99.1)  announcing new one year data  demonstrate
     the  benefits  of  UFE:  shorter  recovery  and  fewer  complications  than
     hysterectomy for Uterine Fibroids.



ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

     (c) Exhibits.

         99.1 The Registrant's Press Release dated March 31, 2003.




 3
                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                           BIOSPHERE MEDICAL, INC.
                                           (Registrant)





Date:       March 31, 2003                 By: /s/ Robert M. Palladino
                                           ________________________________
                                           Executive Vice President and
                                           Chief Financial Officer




 4

EX-99

                                                                     EXIBIT 99.1



CONTACT:
- -------


Paul Looney, CEO and Chairman                         Kathleen Breslin
BioSphere Medical, Inc.                               MS&L
781-681-7920                                          212-213-7076
plooney@biospheremed.com                              kathleen.breslin@mslpr.com
- ------------------------                              --------------------------


Robert Palladino, CFO
Biosphere Medical, Inc.
781-681-7925
bpalladino@biospheremed.com
- ------------------------





     NEW ONE YEAR DATA DEMONSTRATE THE BENEFITS OF UFE: SHORTER RECOVERY AND
           FEWER COMPLICATIONS THAN HYSTERECTOMY FOR UTERINE FIBROIDS

                      Controlling Fibroids Without Surgery

   One-Year Data was Presented at Society of Interventional Radiology Meeting


SALT LAKE CITY, UT 3/31/03  (NASDAQ:BSMD) -- Women with painful uterine fibroids
who choose uterine fibroid embolization (UFE) to treat their symptoms experience
fewer  complications,  stay in the hospital fewer days and return to work faster
than women who have a  hysterectomy,  according  to the results of an  extensive
clinical study conducted at 11 leading edge medical  institutions.  The clinical
trial data,  that was reviewed by the FDA, was presented  Friday,  March 28th at
the Society of  Interventional  Radiology (SIR) annual meeting in Salt Lake City
by renowned  uterine  fibroid  expert Dr.  James Spies,  associate  professor of
Radiology, Georgetown University Hospital, Washington, D.C.

Additionally, women treated with UFE experienced marked reductions in blood loss
and heavy bleeding.  Both treatments were similarly  effective in reducing other
common fibroid symptoms,  including pelvic pain, pelvic discomfort,  and urinary
frequency. UFE is a non-surgical,  uterus-sparing procedure in which tiny emboli
are injected into blood vessels to stop the blood supply to fibroids.

"The results of this study are important because they demonstrate that UFE is an
effective fibroid treatment when compared to hysterectomy," said Dr. Spies, lead
author of the study.  "It offers women a less invasive,  non-surgical  option to
consider  when  discussing  the best  ways to treat  their  symptomatic  uterine
fibroids with their physicians."

Uterine  fibroids are common  benign  tumors that grow from the muscular wall of
the  uterus.  Fibroids  may cause  heavy  bleeding,  pelvic  discomfort,  pelvic
disfigurement,  anemia,  and create  pressure on other  organs.  According  to a
survey  conducted  by the SIR,  57 percent of women with  fibroids  rank them as
"highly  problematic." And, one in five women with fibroids experiences symptoms
that can become so severe and  debilitating  that her  everyday  life is greatly
impacted.  This new medical information from the heavily reviewed clinical study
demonstrates  that women no longer  need to live with the impact of  fibroids on
their  everyday life and surgery is not required to resolve the symptoms  caused
by the fibroids.

                                     PAGE 1


STUDY DETAILS

Women treated with UFE had a shorter mean  hospital  stay than the  hysterectomy
group  (0.83 days vs.  2.3 days,  p<0.001)  as well as a quicker  return to work
(10.7 days vs. 32.5 days,  p<0.001).  The  embolization  group also  experienced
marked  reductions in blood loss scores  (55.6% at 3 months,  58.1% at 6 months,
p<0.001) and menorrhagia scores (46.8% at 3 months,  56.6% at 6 months, 61.3% at
12 months,  p<0.001).  Similar numbers of patients  showed  improvements in bulk
symptoms  at 12  months  in  both  procedures  for  pelvic  pain  (UFE  84%  vs.
hysterectomy 98%,  p=0.021),  pelvic  discomfort (UFE 83% vs.  hysterectomy 95%,
p=0.055),  and urinary  dysfunction  (UFE 80% vs.  hysterectomy  79%,  p=0.819).
Complications  were  substantially  more likely to occur in women  treated  with
hysterectomy  (50%  vs.  27.5%,   p=0.01)  with  a  trend  toward  more  serious
complications.

In the study,  102 women had a UFE procedure using  EmboSphere(R)  Microspheres,
the  first  and  only  cleared  embolic  device  for UFE,  while 50 women  had a
hysterectomy.

"Today,  hysterectomy  is still the primary  treatment for  symptomatic  uterine
fibroids - almost one-third of the 600,000 hysterectomies  performed in the U.S.
each year are for fibroids," said Dr. Spies. "With comparable symptom reduction,
a shorter recovery time, and fewer serious complications than hysterectomy,  UFE
is an option patients may want to consider for treating their fibroids."

The study was  sponsored by  BioSphere  Medical,  Inc.  and was  conducted at 11
clinical centers across the United States.

NON-SURGICAL  UTERUS-SPARING OPTION
UFE is a catheter-based procedure performed by an interventional radiologist. It
has an extensive history and was first described in 1995 by Jean-Jacques Merland
and his  colleagues  at  Hopital  Lariboisiere  in  Paris,  France.  During  the
procedure,  a small  incision is made in the groin and a catheter is guided into
the uterine arteries. Embosphere Microspheres are injected via the catheter into
the blood  vessels that feed the  fibroids.  Over time,  the lack of  nourishing
blood causes the fibroids to shrink,  resulting in symptom reduction. UFE is not
recommended for women who want to have children.

NEW "FIBROID  BLOCKER"
In November 2002, the FDA cleared  BioSphere  Medical's  510(k)  application for
Embosphere  Microspheres in UFE procedures to treat symptomatic  fibroids.  They
are the first and only embolic  device to be cleared for this  indication.  They
have an extensive  clinical history and have been used in more than an estimated
15,000 UFE  procedures  worldwide.  And,  according to company  estimates,  over
30,000 embolization  procedures worldwide have utilized Embosphere  Microspheres
since  their  April  2000  clearance  for use in  hypervascularized  tumors  and
vascular malformations.

Embosphere  Microspheres  are  round,  hydrophilic  beads  made  of  an  acrylic
co-polymer.  The smooth round surface of the beads prevents  clumping within the
catheter and the blood  vessels,  promoting  ease and  accuracy of delivery.  In
addition,  the elasticity of the microspheres  facilitates passage through small
delivery systems.

                                     PAGE 2



ABOUT  BIOSPHERE  MEDICAL,  INC.

BioSphere Medical, Inc., based in Rockland,  Massachusetts,  is a medical device
company  focused on the  management  of tumors  and  vascular  malformations  by
occluding their blood supply.  The company is pioneering the use of patented and
proprietary  bio-engineered  microspheres  as a new class of embolic.  BioSphere
Medical's lead products, Embosphere Microspheres and EmboGold Microspheres, have
been previously cleared by the FDA for the treatment of hypervascularized tumors
and vascular malformations and Embosphere  Microspheres has been cleared for use
in Uterine Fibroid Embolization. BioSphere Medical has received CE Mark approval
in the European Community and approvals in various foreign countries which allow
the company to sell Embosphere Microspheres and EmboGold Microspheres for use in
general embolization  procedures,  including uterine fibroid  embolization.  For
additional  information  about BioSphere  Medical,  see the company's website at
www.biospheremed.com.


CAUTIONARY STATEMENT REGARDING  FORWARD-LOOKING  STATEMENTS - This press release
and the Company's web site contain forward-looking statements within the meaning
of the Private Securities  Litigation Reform Act of 1995,  including  statements
with  respect to the timing and  outcome of the  Company's  regulatory  approval
efforts and the market  opportunity  for  Embosphere  Microspheres  for UFE. The
Company  uses words such as "plans,"  "seeks,"  "projects,"  "believes,"  "may,"
"anticipates,"  "estimates," "should'" and similar expressions to identify these
forward-looking   statements.   These   statements  are  subject  to  risks  and
uncertainties  and are based upon the Company's  beliefs and assumptions.  There
are a  number  of  important  factors  that  may  affect  the  Company's  actual
performance and results and the accuracy of its forward-looking statements, many
of which are beyond the Company's  control and are  difficult to predict.  These
important factors include, without limitation,  risks relating to the failure of
Terumo to successfully  market and sell the company's  products,  the failure of
the Company to achieve or maintain necessary regulatory approvals, either in the
United States or  internationally,  with respect to the  manufacture and sale of
its products;  to successfully  develop,  commercialize  and achieve  widespread
market  acceptance  of the  Embosphere  Microspheres  and  EmboGold  Microsphere
technologies for uterine fibroid  embolization,  targeted liver embolization and
other applications;  to provide patent and other proprietary  protection for the
Company's  products;  the  absence of or delays and  cancellations  of,  product
orders;  delays,  difficulties or unanticipated costs in the introduction of new
products;   competitive  pressures;  the  inability  of  the  Company  to  raise
additional  funds  to  finance  the  development,  marketing,  and  sales of its
products; general economic conditions; as well as those risk factors detailed in
the Company's Quarterly Report on Form 10-K for the year ended December 31, 2002
filed by the Company  with the  Securities  and  Exchange  Commission  and other
periodic  reports filed with the Commission.  In addition,  the  forward-looking
statements   included  in  this  press  release  represent  BioSphere  Medical's
estimates as of the date of this release.  BioSphere  Medical  anticipates  that
subsequent events and developments will cause its estimates to change.  However,
while BioSphere Medical may elect to update these forward-looking  statements at
some point in the future,  it  specifically  disclaims any  obligation to do so.
These  forward-looking  statements  should  not be relied  upon as  representing
BioSphere  Medical's estimates or views as of any date subsequent to the date of
this release.

   For more information on UFE, call 1-877-ASK-4UFE or visit www.ASK4UFE.com.



                                     Page 3